8月4日，爱德华兹生命科学盘中上涨3.1%，报88.74美元/股，成交额1.62亿美元。
消息面上，近期多家华尔街投行密集上调公司评级及目标价。瑞银将评级从中性上调至买入，目标价从90美元大幅提升至110美元；Leerink Partners将评级从与大盘持平上调至跑赢大盘，目标价从87美元升至101美元；Rothschild & Co Redburn将目标价上调至102美元并维持买入评级。
基本面方面，公司二季度调整后每股收益0.78美元，超出市场预期的0.74美元；营收17.41亿美元，同比增长13.7%，超出预期的17.00亿美元。RBC Capital Markets指出，公司在经导管主动脉瓣置换（TAVR）领域具备差异化竞争优势，产品催化剂管线将延续至2027年的双位数增长。此外，医疗保健设备板块整体走强，板块内直觉外科涨5.78%、史赛克涨4.06%，形成联动效应。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.